Skip to main content
Terug
CRL logo

Charles River Laboratories International, Inc.

Datakwaliteit: 100%
CRL
NYSE Healthcare Medical - Diagnostics & Research
€ 158,00
▲ € 4,40 (2,86%)
Marktkapitalisatie: 7,78B
Dagbereik
€ 154,49 € 159,35
52-Weeksbereik
€ 91,86 € 228,88
Volume
602.544
50D / 200D Gem.
€ 186,54 / € 173,06
Vorige Slotkoers
€ 153,60

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -53,9 0,4
P/B 2,5 2,9
ROE % -4,4 3,8
Net Margin % -3,6 3,9
Rev Growth 5Y % 3,2 10,0
D/E 1,0 0,2

Koersdoel Analisten

Hold
€ 202,17 +28.0%
Low: € 175,00 High: € 260,00
Forward K/W
14,3
Forward WPA
€ 11,07
WPA Groei (sch.)
+0,0%
Omzet Sch.
4 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 15,50
€ 15,36 – € 15,63
4,6 B 1
FY2029 € 14,07
€ 13,94 – € 14,19
4,6 B 1
FY2028 € 13,18
€ 13,07 – € 13,30
4,3 B 1

Belangrijkste Punten

Revenue grew 3,20% annually over 5 years — modest growth
Earnings declined -1501,75% over the past year
Generating 518,49M in free cash flow
PEG of 0,05 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 4,05%
Capital efficient — spends only 5,46% of revenue on capex

Groei

Revenue Growth (5Y)
3,20%
Revenue (1Y)-0,85%
Earnings (1Y)-1501,75%
FCF Growth (3Y)19,13%

Kwaliteit

Return on Equity
-4,36%
ROIC6,11%
Net Margin-3,59%
Op. Margin12,65%

Veiligheid

Debt / Equity
0,97
Current Ratio1,29
Interest Coverage4,74

Waardering

P/E Ratio
-53,89
P/B Ratio2,46
EV/EBITDA20,93
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -0,85% Revenue Growth (3Y) -1,39%
Earnings Growth (1Y) -1501,75% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 3,20% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 4,02B Net Income (TTM) -144,34M
ROE -4,36% ROA -2,02%
Gross Margin 30,52% Operating Margin 12,65%
Net Margin -3,59% Free Cash Flow (TTM) 518,49M
ROIC 6,11% FCF Growth (3Y) 19,13%
Safety
Debt / Equity 0,97 Current Ratio 1,29
Interest Coverage 4,74 Dividend Yield 0,00%
Valuation
P/E Ratio -53,89 P/B Ratio 2,46
P/S Ratio 1,94 PEG Ratio 0,05
EV/EBITDA 20,93 Dividend Yield 0,00%
Market Cap 7,78B Enterprise Value 10,63B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4,02B 4,05B 4,13B 3,98B 3,54B
Net Income -144,34M 10,30M 474,62M 486,23M 390,98M
EPS (Diluted) -2,91 0,20 9,22 9,48 7,60
Gross Profit 1,23B 1,33B 1,50B 1,46B 1,33B
Operating Income 507,84M 227,35M 617,26M 650,98M 589,86M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7,14B 7,53B 8,20B 7,60B 7,02B
Total Liabilities 3,92B 4,02B 4,54B 4,58B 4,43B
Shareholders' Equity 3,16B 3,46B 3,60B 2,98B 2,53B
Total Debt 3,07B 2,72B 3,07B 3,10B 3,21B
Cash & Equivalents 213,77M 194,61M 276,77M 233,91M 245,24M
Current Assets 1,45B 1,40B 1,61B 1,44B 1,27B
Current Liabilities 1,12B 994,10M 1,06B 1,09B 1,03B